Analyst Marie Thibault from BTIG reiterated a Buy rating on Outset Medical (OM – Research Report) and keeping the price target at $45.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Marie Thibault has given her Buy rating due to a combination of factors, including the recent appointment of Renee Gaeta as the new Chief Financial Officer at Outset Medical. Gaeta’s previous experience as CFO at Shockwave Medical and her familiarity with Establishment Labs suggests she brings valuable expertise to the company. Her leadership is expected to positively impact Outset Medical’s Information Technology and Human Resources divisions.
Additionally, Outset Medical’s reaffirmation of its full-year 2025 financial guidance, projecting revenue between $115 million and $125 million with adjusted gross margins in the high 30% range, supports a positive outlook. These elements contribute to a stable financial forecast, reinforcing the Buy recommendation. Thibault’s confidence in the company’s strategic direction and financial stability underpins her positive assessment.
Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of OM in relation to earlier this year.